Baxter Alerted FDA To Problem Before Receiving Warning Letter, Firm Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The letter details problems related to Baxter's use of albumin in the manufacturing of its Isolex 300i Magnetic Cell Selection System, a device/biologic regulated as a Class III device.
You may also be interested in...
First-Ever Stem Cell GMP Warning Letter Cites IntelliCell
FDA finds the company failed to establish procedures for a range of GMP basics, which is a problem because according to the agency the IntelliCell adipose tissue-derived stem cells are both a drug and a biologic product.
Baxter Receives Warning Letter For Fibrin Sealant Promotional Materials
An FDA warning letter charges that promotional materials for Baxter's Tisseel fibrin sealant constitute misbranding of the product
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.